Clinical Trials Browser

Interventional × Neoplasm Metastasis × selinexor × Clear all

Neoplasm Metastasis, Neoplasms, Recurrence, Salivary Gland Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04138381 2023-03-27

SeliGIST

Phase 1/2 Unknown

30 enrolled

Sarcoma

Neoplasm Metastasis, Sarcoma, Drug-Related Side Effects and Adverse Reactions

NCT02384850 2022-04-08

SENTINEL

Phase 1 Terminated

10 enrolled 13 charts

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT02283359 2016-01-15

Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus

Phase 1 Terminated

3 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Neoplasm Metastasis, Recurrence, Stomach Neoplasms

Clinical Trials

A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

SeliGIST

SENTINEL

Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus